Exact Mass: 434.29496580000006
Exact Mass Matches: 434.29496580000006
Found 500 metabolites which its exact mass value is equals to given mass value 434.29496580000006,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
3a,7a,12a-Trihydroxy-5b-cholestan-26-al
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-26-al is an intermediate in bile acid biosynthesis. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues (PMID: 11316487, 16037564, 12576301, 11907135). 3a,7a,12a-trihydroxy-5b-cholestane-27-al is an enzymatically generated intermediate in the oxidation process of 5b-cholestane-3a,7a,12a,27-tetrol into 3a,7a,12a-trihydroxy-5b-cholestanoic acid in liver mitochondria. Mitochondrial sterol 27-hydroxylase (EC 1.14.13.60) appears to perform multiple monooxygenations in this conversion. (PMID: 8496170). 3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-26-al is an intermediate in bile acid biosynthesis. Bile acids are steroid acids found predominantly in bile of mammals. The distinction between different bile acids is minute, depends only on presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH and, consequently, require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g., membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. (PMID: 11316487, 16037564, 12576301, 11907135)
3alpha,7alpha-Dihydroxycoprostanic acid
3α,7α-Dihydroxycoprostanic acid is a bile acid excreted in small amounts in the urine of healthy subjects (PMID: 864325). 3α,7α-Dihydroxycoprostanic acid is the precursor to chenodeoxycholic acid, a bile acid. Bile acids are steroid acids found predominantly in the bile of mammals. The distinction between different bile acids is minute, depending only on the presence or absence of hydroxyl groups on positions 3, 7, and 12. Bile acids are physiological detergents that facilitate excretion, absorption, and transport of fats and sterols in the intestine and liver. Bile acids are also steroidal amphipathic molecules derived from the catabolism of cholesterol. They modulate bile flow and lipid secretion, are essential for the absorption of dietary fats and vitamins, and have been implicated in the regulation of all the key enzymes involved in cholesterol homeostasis. Bile acids recirculate through the liver, bile ducts, small intestine, and portal vein to form an enterohepatic circuit. They exist as anions at physiological pH, and consequently require a carrier for transport across the membranes of the enterohepatic tissues. The unique detergent properties of bile acids are essential for the digestion and intestinal absorption of hydrophobic nutrients. Bile acids have potent toxic properties (e.g. membrane disruption) and there are a plethora of mechanisms to limit their accumulation in blood and tissues. 3a,7a-Dihydroxycoprostanic acid is a bile acid excreted in small amounts in the urine of healthy subjects (PMID 864325)
beta-Citraurol
beta-Citraurol is found in citrus. beta-Citraurol is a constituent of citrus hybrid peel Constituent of citrus hybrid peel. beta-Citraurol is found in citrus.
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C is found in mushrooms. (12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C is a constituent of Hericium erinaceum (lions mane)
Polysorbate 60
Polysorbate 60 is an emulsifier, opacifier, protective coating, dough conditioner, dispersant, wetting agent, stabiliser, defoamer, poultry scald agent, flavour.Polysorbates are a class of emulsifiers used in some pharmaceuticals and food preparation. They are often used in cosmetics to solubilize essential oils into water-based products. Polysorbates are oily liquids derived from PEG-ylated sorbitan (a derivative of sorbitol) esterified with fatty acids. (Wikipedia). Emulsifier, opacifier, protective coating, dough conditioner, dispersant, wetting agent, stabiliser, defoamer, poultry scald agent, flavour.
Butyl oleate sulfate
C22H42O6S (434.27019520000005)
Surfactant. Butyl oleate sulfate is used in dehydration of grapes to produce raisins and as a coating for citrus fruits. Surfactant. It is used in dehydration of grapes to produce raisins and as a coating for citrus fruits
Erinacine C
Erinacine C is found in mushrooms. Erinacine C is a metabolite of Hericium erinaceum (lions mane).
3alpha,7alpha,24(S)-trihydroxy-5beta-cholestan-27-al
3alpha,7alpha,24(S)-trihydroxy-5beta-cholestan-27-al is considered to be practically insoluble (in water) and relatively neutral
24-Fluorocalcitriol
Anhydro-5alpha-cyprinol
Urea, N-butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)-
Ribociclib
C23H30N8O (434.25424499999997)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0)
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0)
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0)
DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0)
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)+=O(5))
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)+=O(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/2:0)
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)+=O(15))
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)+=O(15)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0)
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/2:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0)
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/2:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0)
DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0)
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
DG(2:0/0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/2:0)
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0)
DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0)
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
DG(2:0/0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/2:0)
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
[16]-Gingerol
[16]-gingerol is a member of the class of compounds known as gingerols. Gingerols are compounds containing a gingerol moiety, which is structurally characterized by a 4-hydroxy-3-methoxyphenyl group substituted at the C6 carbon atom by a 5-hydroxy-alkane-3-one. [16]-gingerol is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). [16]-gingerol can be found in ginger, which makes [16]-gingerol a potential biomarker for the consumption of this food product.
3beta-Malonyloxy-15-acetoxy-ent-labda-7,13E-dien methylester
methyl 2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate
(E)-(24R)-5alpha-cholest-22-ene-3beta,6alpha,15beta,24-tetrol|certonardosterol G
1alpha-(beta-D-glucopyranosyloxy)eudesma-3alpha,4beta,11-triol
9,10-diangeloyloxy-11-hydroxy-10,11-dihydrobrickelliol
6alpha-isobutyryloxy-7beta-acetoxy-13-Z-kolavenic acid
Tri-Ac-(3beta,5alpha,16alpha,17alpha)-Androstane-3,16,17-triol
3beta,11alpha-dihydroxy-5beta,6beta-epoxy-9,11-secocholestan-9-one
methyl rel-(1R,2S)-(1-farnesyl-2-hydroxy-4-oxocyclopentan-1-yl)-3-ethoxypropanoate
(-)-3-O-palmitoylloliolide
A natural product found in Parasenecio deltophyllus.
15-(3-Hydroxy-2-methylbutanoyl)-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid
6alpha,8alpha-dihydroxy-23-carboxy-labd-13(14),17-dien-16,19-olide
(3beta, 5alpha, 22R, 23S)-22-Chlorocholesta-8, 14-diene-3, 23-diol, 9CI
7-oxo-13alpha-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine U
(3S,5R,6S,7E)-3-tetradecanoate-5,6-epoxy-beta-ionone
3,21-Di-Ac-(3alpha,5beta)-3,14,21-Trihydroxypregnan-20-one
3,21-Di-Ac-(3beta,5alpha,17alphaOH)-3,17,21-Trihydroxypregnan-20-one
(3beta,5alpha,6beta,11beta,22E)-cholest-22-ene-3,5,6,11-tetrol|menellsteroid B
17-Angeloyl-(ent-12alpha,16alphaOH)-12,16,17-Trihydroxy-19-kauranoic acid|ent-12alpha,16alpha-dihydroxy-17-angeloxykauran-19-oic acid
8alpha,15(S),23alpha-trihydroxy-23,6alpha-epoxy-labd-13(14),17-dien-16(S),19-olide
3,4-Seco-5beta-cholestandisaeure-(3,4)|3.4-Seco-5beta-cholestandisaeure-(3.4)|3.4-seco-5beta-cholestanedioic acid-(3.4)
(2S,4aS,5S,6R,8aS)-5-(2-((1S,3aS,5R,8aS,Z)-1-hydroxy-1,4,4,6-tetramethyl-1,2,3,3a,4,5,8,8a-octahydroazulen-5-yl)ethyl)-4a,6-dimethyloctahydro-2H-chromene-2,6-diol
(3S,5E,7E,10S)-9,10-Secocholesta-5,7-diene-3,23,25,26-tetrol
(10R,6E)-7,11-dimethyl-3-methylene-6-dodecaene-1,2,10,11-tetraol 10-O-beta-D-glucopyranoside|trikamsesquiside A
3beta,16alpha-dihydroxy-(5alpha)-cholestan-21-oic acid|3beta,16alpha-dihydroxy-5alpha,17beta-cholestan-21-carboxylic acid
2-hydroxy-3-[(1-oxododecyl)oxy]propyl-beta-D-glucopyranoside
(7alpha)-7-[4-(2-hydroxy-1-methylethyl)benzyl]abieta-8,11,13-trien-12-ol|ferrugimenthenol
ent-19-(Z)-coumaroyloxylabda-8(17),13(16),14-triene
2xi, 12R-2-(2-hydroxyheptadecyl)-2-methoxy-1-oxaspiro[4.5]deca-6.9-dien-8-one|2xi,12R-2-(2-hydroxyheptadecyl)-2-methoxy-1-oxaspiro[4.5]deca-6.9-dien-8-one|amomol A|amomol B
Na, Nb-Didemethylisoalfileramine|Na,Nb-Di-de-Me-Isoalfileramine
C28H38N2O2 (434.29331279999997)
abiesadine V|methyl 7-oxo-13beta-hydroxy-8,11,13-abietatriene-18-succinate
12beta,16beta,22-trihydroxy-24alpha-methylscalar-25beta,24alpha-olide
1beta,3beta,5alpha-trihydroxycholestan-6-one|menellsteroid D
(3beta, 5alpha, 6beta, 9alpha)-Cholest-7-ene-3, 5, 6, 9-tetrol, 9CI
(3beta, 7beta, 9alpha)-Cholest-5-ene-3, 7, 9, 19-tetrol
(1beta,3beta,16beta,22S)-cholest-5-ene-1,3,16,22-tetrol|(22S)-Cholest-5-ene-1beta,3beta,16beta,22-tetraol|(22S)-cholest-5-ene-1beta,3beta,16beta,22-tetrol|Alliosterol|cholest-5-ene-1(R*),3(R*),16(S*),22(S*)-tetraol
3alpha-acetoxy-7alpha-hydroxy-5beta-cholan-24-oic acid
Tri-Ac-(3beta,5alpha,6alpha,17alpha)-Androstane-3,6,17-triol
methyl-18-(2-methylbutyryloxy)-grindeloate|methyl-18-<2-methylbutyryloxy>-grindeloate
(20R,24S)-3beta,6beta,24-trihydroxy-5alpha-cholestan-15-one
longipinane-7beta,8alpha,9alpha-triol-1-one 7-angelate-8-methylbutyrate
methyl-17-(2-methylbutyryloxy)-grindeloate|methyl-17-<2-methylbutyryloxy>-grindeloate
6alpha,8alpha,15(S)-trihydroxy-23-oxo-labd-13(14),17-dien-16(S),19-olide
9beta-acetoxy-11beta,12beta-epoxy-13alpha-hydroxy-3alpha-propionoxy-1beta,8beta-trinervit-15(17)-ene
2alpha-Angeloyloxy-3beta-(2-methylbutanoyloxy)isodrimeninol
(ent-15beta)-2,3-Dihydroxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid|2,3-Dihydroxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid
8-Angeloyl,9-(3-mehtylbutanoyl)-(3beta,8alpha,9beta,10b)-8,9,10-Trihydroxy-5-longipinanone
11-hydroxy-8,11,13-abietatriene 12-O-beta-D-xylopyranoside
13-oxo-7-[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxytetradecanoic acid
[(2R)-2-[(E,2S,4R)-4,6-dimethyloct-6-en-2-yl]-6-oxo-2,3-dihydropyran-3-yl] (2E,4E,6S)-8-hydroxy-6-(hydroxymethyl)-4-methylocta-2,4-dienoate
Bis[2-(2-butoxyethoxy)ethyl] adipate
CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9768; ORIGINAL_PRECURSOR_SCAN_NO 9763 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9764; ORIGINAL_PRECURSOR_SCAN_NO 9760 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9787; ORIGINAL_PRECURSOR_SCAN_NO 9784 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9800; ORIGINAL_PRECURSOR_SCAN_NO 9798 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9802; ORIGINAL_PRECURSOR_SCAN_NO 9800 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9812; ORIGINAL_PRECURSOR_SCAN_NO 9809
Ala Phe Val Val
Ala Val Phe Val
Ala Val Val Phe
Phe Ala Val Val
Phe Gly Ile Val
Phe Gly Leu Val
Phe Gly Val Ile
Phe Gly Val Leu
Phe Ile Gly Val
Phe Ile Val Gly
Phe Leu Gly Val
Phe Leu Val Gly
Phe Val Ala Val
Phe Val Gly Ile
Phe Val Gly Leu
Phe Val Ile Gly
Phe Val Leu Gly
Phe Val Val Ala
Gly Phe Ile Val
Gly Phe Leu Val
Gly Phe Val Ile
Gly Phe Val Leu
Gly Ile Phe Val
Gly Ile Val Phe
Gly Leu Phe Val
Gly Leu Val Phe
Gly Val Phe Ile
Gly Val Phe Leu
Gly Val Ile Phe
Gly Val Leu Phe
Ile Phe Gly Val
Ile Phe Val Gly
Ile Gly Phe Val
Ile Gly Val Phe
Ile Val Phe Gly
Ile Val Gly Phe
Leu Phe Gly Val
Leu Phe Val Gly
Leu Gly Phe Val
Leu Gly Val Phe
Leu Val Phe Gly
Leu Val Gly Phe
Val Ala Phe Val
Val Ala Val Phe
Val Phe Ala Val
Val Phe Gly Ile
Val Phe Gly Leu
Val Phe Ile Gly
Val Phe Leu Gly
Val Phe Val Ala
Val Gly Phe Ile
Val Gly Phe Leu
Val Gly Ile Phe
Val Gly Leu Phe
Val Ile Phe Gly
Val Ile Gly Phe
Val Leu Phe Gly
Val Leu Gly Phe
Val Val Ala Phe
Val Val Phe Ala
1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / 1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5Z,7E)-(1R,3R)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene3-oxide
(5Z,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatrien 3-oxide
1α,25-dihydroxy-22-thiavitamin D3 / 1α,25-dihydroxy-22-thiacholecalciferol
1α,25-dihydroxy-22-thia-20-epivitamin D3 / 1α,25-dihydroxy-22-thia-20-epicholecalciferol
1α,25-dihydroxy-23-thiavitamin D3 / 1α,25-dihydroxy-23-thiacholecalciferol
(5Z,7E)-(1S,3R,24R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrol
(5Z,7E)-(1S,3R,24S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,24,25-tetrol
(5Z,7E)-(1S,3R,25R)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
(5Z,7E)-(1S,3R,25S)-22-oxa-9,10-seco-5,7,10(19)-cholestatriene-1,3,25,26-tetrol
(5Z,7E)-(1S,3R)-24-(dimethylphosphoryl)-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
C26H43O3P (434.29496580000006)
(5Z,7E)-(1S,3R,24R)-25-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,24-triol
(5Z,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
(5Z,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
(5E,7E,10Z)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
(5E,7E,10E)-(1S,3R)-19-fluoro-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol
24R-fluoro-1α,25-dihydroxyvitamin D3 / 24R-fluoro-1α,25-dihydroxycholecalciferol
(7E)-(1R,2S,3R)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
(7E)-(1R,2R,3R)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
(7E)-(1R,2S,3R,20S)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
(7E)-(1R,2R,3R,20S)-2-hydroxymethyl-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
(5Z,7E)-(1S,3R,10S)-9,10-seco-5,7-cholestadiene-1,3,19,25-tetrol
(5Z,7E)-(1S,3R,10R)-9,10-seco-5,7-cholestadiene-1,3,19,25-tetrol
2β-fluoro-1α,25-dihydroxyvitamin D3
1,24-Dihydroxy-25-fluorovitamin D3
1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / 1alpha,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5E,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene 3-oxide
(25R)-3alpha,7alpha-dihydroxy-5beta-cholestan-26-oic acid
(25R)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-al
The (25R)-diastereomer of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-al.
3alpha,12alpha,25-Trihydroxy-5beta-cholestan-7-one
3beta,12alpha-Dihydroxy-5beta-cholestan-26-oic acid
3alpha,12alpha-Dihydroxy-5beta-cholestan-26-oic acid
3alpha,7beta-Dihydroxy-5beta-cholestan-26-oic acid
3alpha,7alpha-Dihydroxy-5beta-cholestan-26-oic acid
A cholestanoid that is 5beta-cholestan-26-oic acid substituted by alpha-hydroxy groups at positions 3 and 7 respectively.
5alpha-Cholest-25-ene-3alpha,7alpha,12alpha,26-tetrol
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-23-one
5beta-Cholest-25-ene-3alpha,7alpha,12alpha,23-tetrol
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholestan-24-one
5beta-Cholest-25-ene-3alpha,7alpha,12alpha,24-tetrol
7alpha,12alpha,26-Trihydroxy-5beta-cholestan-3-one
7alpha,12alpha,25-Trihydroxy-5beta-cholestan-3-one
5beta-Cholest-25-ene-3alpha,7alpha,12alpha,26-tetrol
3alpha,7alpha-Dihydroxy-5alpha-cholestan-26-oic acid
3beta,7alpha-Dihydroxy-5alpha-cholestan-26-oic acid
3alpha,7alpha,12alpha-Trihydroxy-5beta-23E-cholestan-26-oic acid
CJ 14258
b-Citraurinol
butyl oleate sulfate
C22H42O6S (434.27019520000005)
Apadoline
1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5E)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5Z)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
1alpha,25-dihydroxy-22-thiavitamin D3
1alpha,25-dihydroxy-22-thia-20-epivitamin D3
1alpha,25-dihydroxy-23-thiavitamin D3
(24R)-1alpha,24,25-trihydroxy-22-oxavitamin D3 / (24R)-1alpha,24,25-trihydroxy-22-oxacholecalciferol
(24S)-1alpha,24,25-trihydroxy-22-oxavitamin D3 / (24S)-1alpha,24,25-trihydroxy-22-oxacholecalciferol
(25R)-1alpha,25,26-trihydroxy-22-oxavitamin D3 / (25R)-1alpha,25,26-trihydroxy-22-oxacholecalciferol
(25S)-1alpha,25,26-trihydroxy-22-oxavitamin D3 / (25S)-1alpha,25,26-trihydroxy-22-oxacholecalciferol
1alpha-hydroxy-24-(dimethylphosphoryl)-25,26,27-trinorvitamin D3
C26H43O3P (434.29496580000006)
(24R)-25-fluoro-1alpha,24-dihydroxyvitamin D3
(10Z)-19-fluoro-1alpha,25-dihydroxyvitamin D3 / (10Z)-19-fluoro-1alpha,25-dihydroxycholecalciferol
(10E)-19-fluoro-1alpha,25-dihydroxyvitamin D3 / (10E)-19-fluoro-1alpha,25-dihydroxycholecalciferol
24R-fluoro-1alpha,25-dihydroxyvitamin D3
2beta-fluoro-1alpha,25-dihydroxyvitamin D3
4-(TERT-BUTYLDIMETHYLSILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)ETHYL]TETRAHYDROPYRAN-2-ONE
2-methyl-2-(2-methylundecan-2-yltrisulfanyl)undecane
methyl 2-[[(2E)-2-benzylideneoctylidene]amino]benzoate
(S)-1-CYCLOHEXYL-4-(4-(2-METHOXYPHENYL)PIPERAZIN-1-YL)-2-METHYL-2-PHENYLBUTAN-1-ONE
C28H38N2O2 (434.29331279999997)
2-(4-piperazin-1-ylanilino)-N-(4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl)pyrimidine-4-carboxamide
sodium hydrogen N-(1-oxooctadecyl)-L-glutamate
C23H41NNaO5 (434.2882276000001)
2-[2-(2,3-dihydro-5-methoxy-2,3,3-trimethyl-1H-indol-1-yl)vinyl]-1,3,3-trimethyl-3H-indolium acetate
N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine,formaldehyde,2-[(2-methylphenoxy)methyl]oxirane,phenol
Dimethyl ocatadecyl aminoium hydroxy propylsulfonate
C23H48NO4S (434.33038680000004)
Oxogestone phenpropionate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
(1R,3S,5E)-5-[(2E)-2-[(3aS,7aR)-1-[1-(2-hydroxy-2-methylpropyl)sulfanylpropan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
(1R)-4-[(1E,3E,5E,7Z,9E,11Z,13E,15E)-17-Hydroxy-3,7,12,16-tetramethylheptadeca-1,3,5,7,9,11,13,15-octaen-1-YL]-3,5,5-trimethylcyclohex-3-EN-1-OL
Ribociclib
C23H30N8O (434.25424499999997)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide/(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(24R)-1alpha,24,25-trihydroxy-22-oxavitamin D3/(24R)-1alpha,24,25-trihydroxy-22-oxacholecalciferol
(2R)-2-acetamido-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]sulfanylpropanoate
C25H40NO3S- (434.2728750000001)
13-(Hydroxymethyl)-2,5-dimethyl-8-propan-2-yl-15,20,22-trioxapentacyclo[12.8.0.02,10.05,9.016,21]docosa-8,12-diene-17,18-diol
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0)
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0)
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)
(5Z)-5-[(2E)-2-[1-(5-fluoro-6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
[3,9-Dicarboxy-2,10-dihydroxy-5-methyl-4,8-dioxo-11-(trimethylazaniumyl)undecyl]-trimethylazanium
2-[(2R)-2-hydroxyheptadecyl]-2-methoxy-1-oxaspiro[4.5]deca-6,9-dien-8-one
28-Norteasterone
A brassinosteroid that is 6-deoxo-28-norteasterone carrying an oxo group at position 6.
(24S)-7alpha,12alpha,24-trihydroxy-5beta-cholestan-3-one
7alpha,12alpha,24-Trihydroxy-5beta-cholestan-3-one with S-configuration at C-24.
1-[[(2R,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
(8R,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
cyclohexyl-[(2S,3R)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclohexyl-[(2R,3R)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
1-[[(2S,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[(4R,7R,8S)-5-ethyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
(8S,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
cyclohexyl-[(2S,3S)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclohexyl-[(2R,3S)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
(25S)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-al
The (25S)-diastereomer of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-al.
(6R)-6-[(3R,5S,7R,10S,13R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptanoic acid
[1-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] butanoate
[1-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] hexanoate
[1-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-3-hydroxypropan-2-yl] acetate
(1-hydroxy-3-octoxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-3-hydroxypropan-2-yl] octanoate
[(4E,8E)-2-acetamido-3-hydroxytrideca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-carboxy-2-[(7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoyl]oxypropyl]-trimethylazanium
C26H44NO4+ (434.32701640000005)
2,3-dihydroxypropyl (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[(4E,8E)-3-hydroxy-2-(propanoylamino)dodeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
13-Oxo-7-[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxytetradecanoic acid
(1-hydroxy-3-propanoyloxypropan-2-yl) (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
(1-heptanoyloxy-3-hydroxypropan-2-yl) (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
(1-hydroxy-3-pentanoyloxypropan-2-yl) (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[(2S)-2,3-dihydroxypropyl] (5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoate
2-[Carboxy-(3-dodecanoyloxy-2-hydroxypropoxy)methoxy]ethyl-trimethylazanium
3alpha,7alpha,12alpha-trihydroxy-5beta-cholestan-26-al
A cholestanoid that is 5beta-cholestan-26-al substituted by hydroxy groups at positions 3, 7 and 12 respectively.
(2R)-2-[(2R,3R,4S)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-hydroxyethyl dodecanoate
(24S)-3alpha,7alpha,24-trihydroxy-5beta-cholestan-26-al
3alpha,7alpha,24-trihydroxy-5beta-cholestan-26-al with S-configuration at C-24.
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C
7alpha,12alpha,24-trihydroxy-5beta-cholestan-3-one
amomol A
An oxaspiro compound that is 1-oxaspiro[4.5]deca-6,9-dien-8-one substituted by a (2R)-2-hydroxyheptadecyl moiety and a methoxy group at position 2. It is isolated from the leaves of Amomum aculeatum and exhibits anticancerous efficacy against human lung carcinoma, hormone-dependent human prostate carcinoma and human breast carcinoma.
amomol B
An oxaspiro compound that is 1-oxaspiro[4.5]deca-6,9-dien-8-one substituted by a (2R)-2-hydroxyheptadecyl moiety and a methoxy group at position 2. A natural product found in Amomum aculeatum.
DG(24:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
TG(22:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
INCB38579
INCB38579 is an orally active, highly brain penetrable, and selective histamine H4 receptor (HH4R) antagonist (hH4R IC50=4.8 nM, mH4R IC50=42 nM, rH4R IC50=32 nM). INCB38579 shows anti-inflammatory pain and anti-pruritic activities[1].